(R)- 3- 氨基四氢呋喃 | 111769-26-7

• 物质功能分类: 有机原料 - 氨基化合物 - 环烷胺、芳香单胺、芳香多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 中文名称: (R)- 3- 氨基四氢呋喃
• 中文别名: (R)-3-氨基四氢呋喃；(R)-四氢呋喃-3-胺；(R)4-氨基四氢呋喃；S(-)3-氨基四氢呋喃
• 英文名称: (R)-tetrahydrofuran-3-amine
• 英文别名: (R)-3-aminotetrahydrofuran；(3R)-tetrahydrofuran-3-amine；(3R)-oxolan-3-amine；3-(R)-aminotetrahydrofuran
• CAS: 111769-26-7
• 化学式: C₄H₉NO
• mdl: MFCD06738925
• 分子量: 87.1216
• InChiKey: MIPHRQMEIYLZFZ-SCSAIBSYSA-N

物化性质

• 沸点：
  126℃
• 密度：
  0.997
• 闪点：
  37℃
• 溶解度：
  DMF：30mg/mL； DMSO：30mg/mL；乙醇：30mg/mL； PBS（pH 7.2）：10 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  6
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2932190090
• 包装等级：
  III
• 危险类别：
  3,8
• 危险性防范说明：
  P210,P280,P301+P312+P330,P302+P352,P305+P351+P338+P310
• 危险品运输编号：
  2924
• 危险性描述：
  H225,H302,H315,H318

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (R)-3-Aminotetrahydrofuran
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (R)-3-Aminotetrahydrofuran
CAS number: 111769-26-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H9NO
Molecular weight: 87.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介

(R)-3-氨基四氢呋喃是一种医药中间体，常用于合成抗心律失常药物 Tecadenoson。因此，其合成具有重要的应用价值。

应用

(R)-3-氨基四氢呋喃可作为多种合成和医药中间体，主要用于实验室研发过程以及医药化工生产过程中。

反应信息

• 作为反应物：
  描述：

  (R)- 3- 氨基四氢呋喃 在 4-二甲氨基吡啶 、 二碳酸二叔丁酯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 生成 (R)-tert-Butyl (tetrahydrofuran-3-yl)carbamate
  参考文献：
  名称：

  结合方酰胺衍生的 P2 配体的有效 HIV-1 蛋白酶抑制剂：设计、合成和生物学评估。

  摘要：

  我们描述了新型 HIV-1 蛋白酶抑制剂的设计、合成和生物学评价，该抑制剂含有方酰胺衍生支架作为 P2 配体，并结合 (R)-羟乙胺磺酰胺等排体。具有 N-甲基-3-(R)-氨基四氢呋喃基方酰胺 P2-配体的抑制剂 3h 显示出 0.51 nM 的 HIV-1 蛋白酶抑制 Ki 值。 3小时的能量最小化模型揭示了HIV-1蛋白酶活性位点和四氢呋喃基方酰胺支架之间的主要分子相互作用，这可能是其有效活性的原因。

  DOI：

  10.1016/j.bmcl.2019.08.006
• 作为产物：
  描述：

  (R)-tetrahydrofuran-3-amine hydrochloride 在 2-叔丁基-1,1,3,3-四甲基胍 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.67h， 生成 (R)- 3- 氨基四氢呋喃
  参考文献：
  名称：

  [EN] PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES
  [FR] DÉRIVÉS DE PURINE DESTINÉS À ÊTRE UTILISÉS POUR LE TRAITEMENT DE MALADIES ALLERGIQUES, INFLAMMATOIRES ET INFECTIEUSES

  摘要：

  式（I）的化合物：其中R1为C1-6烷基氨基或C1-6烷氧基；m为3、4或5的整数；n为0至3的整数；p为1或2的整数及其盐是人类干扰素的诱导剂。诱导人类干扰素的化合物可能在治疗各种疾病方面有用，例如治疗过敏性疾病和其他炎症性疾病，例如过敏性鼻炎和哮喘，治疗传染病和癌症，也可能作为疫苗佐剂有用。

  公开号：

  WO2010018130A1

文献信息

• [EN] PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PYRROLO[2,3-D]PYRIMIDINE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：SENTINEL ONCOLOGY LTD

  公开号：WO2021074251A1

  公开（公告）日：2021-04-22

  The invention provides compounds of the formula (1): or a salt or tautomer thereof wherein A, R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are inhibitors of Wee1 and/or PLK1 kinase and are envisaged to be useful in the treatment of cancers.

  这项发明提供了式（1）的化合物：或其盐或互变异构体，其中A、R1、R2、R3、R4、R5和R6如本文所定义。这些化合物是Wee1和/或PLK1激酶的抑制剂，预计在癌症治疗中有用。
• [EN] HEPATITIS C INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE L'HÉPATITE C
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013026163A1

  公开（公告）日：2013-02-28

  A compound of formula (I) useful for the treatment or prevention of hepatitis C viral infection, (Formula (I)) wherein: X1 and X2 are each independently CRB or N; RB is H, (C1-6)alkyl, (C1-6)haloalkyl, halo. -O-(C1-6)alkyl, NH2, NH(C1-6)alkyl or N((C1-6)alkyl)2; R1 and R2 are each independently (C1-6)alkyl optionally mono- or di-substituted with -O-(C1-6)alkyl, NH2, NH(C1-6)alkyl or N((C1-6)alkyl)2; or R1 and R2, together with the carbon to which they are attached, are linked to form a (C3-7)cycloalkyl group or a 3- to 7-membered heterocyclyl, said cycloalkyl and heterocyclyl being optionally mono- or di-substituted with -(C1-6)alkyl; RA is -C(=O)N(R3)(R4), -C(=O)O(R4), heterocyclyl or heteroaryl, wherein each said heterocyclyl and heteroaryl is optionally substituted 1 to 3 times with R41; R5 and R6 are each independently H or (C1-6)alkyl optionally mono- or di-substituted with -O-(C1-6)alkyl, NH2, NH(C1-6)alkyl or N((C1-6)alkyl)2; or R5 and R6, together with the carbon to which they are attached, are linked to form a (C3-7)cycloalkyl group or a 3- to 7-membered heterocyclyl, said cycloalkyl and heterocyclyl being optionally mono- or di-substituted with -(C1-6)alkyl; and n is 0, 1 or 2.

  一种化合物，其化学式为（I），用于治疗或预防丙型肝炎病毒感染，其中：X1和X2分别独立地为CRB或N；RB为H，（C1-6）烷基，（C1-6）卤代烷基，卤基，-O-（C1-6）烷基，NH2，NH（C1-6）烷基或N（（C1-6）烷基）2；R1和R2分别独立地为（C1-6）烷基，可选择地单取代或双取代为-O-（C1-6）烷基，NH2，NH（C1-6）烷基或N（（C1-6）烷基）2；或者R1和R2与它们连接的碳原子一起形成（C3-7）环烷基或3-至7-成员杂环烷基，所述环烷基和杂环烷基可选择地单取代或双取代为-（C1-6）烷基；RA为-C（=O）N（R3）（R4），-C（=O）O（R4），杂环烷基或杂芳基，其中每个所述杂环烷基和杂芳基可选择地用R41取代1至3次；R5和R6分别独立地为H或（C1-6）烷基，可选择地单取代或双取代为-O-（C1-6）烷基，NH2，NH（C1-6）烷基或N（（C1-6）烷基）2；或者R5和R6与它们连接的碳原子一起形成（C3-7）环烷基或3-至7-成员杂环烷基，所述环烷基和杂环烷基可选择地单取代或双取代为-（C1-6）烷基；n为0、1或2。
• HIV INTEGRASE INHIBITORS
  申请人：ViiV Healthcare Company

  公开号：US20150225399A1

  公开（公告）日：2015-08-13

  The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

  本发明具有作为HIV整合酶抑制剂的化合物，因此在抑制HIV复制、预防及/或治疗HIV感染以及治疗艾滋病及/或艾滋病相关综合症方面具有用途。
• [EN] HISTONE METHYLTRANSFERASE INHIBITORS<br/>[FR] INHIBITEURS DE L'HISTONE MÉTHYLTRANSFÉRASE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2018119208A1

  公开（公告）日：2018-06-28

  The present disclosure provides certain angular tricyclic compounds that are histone methyltransi erases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies (e.g., beta- thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本公开提供了一些角三环化合物，这些化合物是组蛋白甲基转移酶G9a和/或GLP的抑制剂，因此可用于治疗可以通过抑制G9a和/或GLP来治疗的疾病，例如癌症和血红蛋白病（例如，β-地中海贫血和镰状细胞病）。还提供了含有这些化合物的药物组合物以及制备这些化合物的方法。
• [EN] INHIBITORS OF APOL1 AND USE OF THE SAME<br/>[FR] INHIBITEURS D'APOL1 ET LEUR UTILISATION
  申请人：VERTEX PHARMA

  公开号：WO2021252859A1

  公开（公告）日：2021-12-16

  The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

  本公开提供了至少一种化合物、重氢化衍生物或药用可接受的盐，选自公式(I)化合物、其重氢化衍生物以及任何前述物质的药用可接受的盐，包含同一的组成物，以及制造和使用同一的方法，包括用于治疗APOL1介导的肾脏疾病。